Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2001;97:409-416
© 2001 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by VALVERDE, J. J.
Right arrow Articles by DÍAZ-RUBIO, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VALVERDE, J. J.
Right arrow Articles by DÍAZ-RUBIO, E.

ORIGINAL RESEARCH

Prognostic Value of DNA Quantification in Early Epithelial Ovarian Carcinoma

J. J. VALVERDE, MD, PhD, M. MARTIN, MD, PhD, J. A. GARCÍA-ASENJO, MD, PhD, A. CASADO, MD, J. A. VIDART, MD, PhD and E. DÍAZ-RUBIO, MD, PhD

From the Departments of Oncology, Gynecology, and Pathology; University Clinic Hospital San Carlos, Madrid, Spain.

Address reprint requests to: Juan Jose Valverde, MD, PhD, Hospital Arrixaca, Servicio de Oncologia Medica, 30120 Murcia, Spain, E-mail: jjvalv{at}teleline.es

Objective: To evaluate the prognostic value of flow cytometric DNA quantification and immunohistochemical expression of c-erbB-2 and p53, and traditional clinicopathologic variables in stages I–II invasive epithelial ovarian cancer.

Methods: We retrospectively reviewed 77 cases of stages I–II ovarian cancer after comprehensive surgical staging. We recorded anthropometric data (age, menopausal status, weight loss, Karnofsky index) and pathologic variables (tumor size, bilaterality, capsular status, ascites, peritoneal cytology, histologic type, and grade). In 72 cases representative paraffin-embedded samples were available for DNA quantification and immunohistochemical evaluation of c-erbB-2 and p53 overexpression. Most women (87%) had received cisplatin-based adjuvant chemotherapy.

Results: The median follow-up was 90 months (range 50–148 months). The 6-year overall disease-free survival rate was 70% (95% confidence interval [CI] 60%, 81%), and overall global survival was 77% (95% CI 67%, 87%). Multivariable analysis using Cox stepwise regression identified DNA content (odds ratio [OR] 12.3; P < .001) and stage (OR 1.4, P = .09) as independent poor prognosis factors for relapse, and DNA content (OR 9.8, P < .001) as the main independent factor for survival. In stepwise discriminant analysis the combination of DNA content and stage provided a correct prediction of relapse in 78% of women.

Conclusion: Flow cytometric DNA quantification was the main independent prognostic factor of relapse and survival in these women with stages I–II epithelial ovarian cancer.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Obstetricians and Gynecologists.